Commentary: Reporting standards are needed for evaluations of risk reclassification.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  International Journal of Epidemiology

• Publication date

  2011-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/ije/dyr083PMID 21571811PMCID PMC3156371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strengthening the reporting of genetic risk prediction studies: the GRIPS statement.

  2011cited by this paper
• Practice of Epidemiology Problems With Risk Reclassification Methods for Evaluating Prediction Models

  2011cited by this paper
• Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

  2011cited by this paper
• Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement

  2011cited by this paper
• Strengthening the reporting of genetic risk prediction studies: the GRIPS statement

  2011cited by this paper
• Evaluating the incremental value of new biomarkers with integrated discrimination improvement.

  2011cited by this paper
• Use of reclassification for assessment of improved prediction: an empirical evaluation.

  2011cited by this paper
• One statistical test is sufficient for assessing new predictive markers

  2011cited by this paper
• Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures

  2009cited by this paper
• Assessing the Value of Risk Predictions by Using Risk Stratification Tables

  2008cited by this paper
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

  2008cited by this paper
• Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction

  2007cited by this paper

• Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and Elaboration. Translation into Russian

  2023cites this paper
• Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Russian translation

  2022cites this paper
• Utility of the “omics” in kidney disease: Methods of analysis, sampling considerations, and technical approaches in renal biomarkers

  2020cites this paper
• Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT)

  2018cites this paper
• Identifying Persons at Increased Risk of Cardiovascular Disease

  2016cites this paper
• Novel metrics for risk stratification with nuclear cardiology.

  2016cites this paper
• Net Reclassification Improvement.

  2016cites this paper
• How to Develop, Validate, and Compare Clinical Prediction Models Involving Radiological Parameters: Study Design and Statistical Methods

  2016influential citation
• Quantifying the value of biomarkers for predicting mortality.

  2015cites this paper
• Risk reclassification analysis investigating the added value of fatigue to sickness absence predictions

  2015cites this paper
• Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration

  2015cites this paper
• Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and

  2015cites this paper
• Risk prediction models for cardiovascular disease and overall mortality

  2014cites this paper
• Complex signals bioinformatics: evaluation of heart rate characteristics monitoring as a novel risk marker for neonatal sepsis

  2014cites this paper
• Learning to prevent healthcare-associated infections: leveraging data across time and space to improve local predictions

  2014cites this paper
• What to expect from net reclassification improvement with three categories

  2014cites this paper
• Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide.

  2014cites this paper
• Net Reclassification Improvement: Computation, Interpretation, and Controversies

  2014cites this paper
• Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease.

  2014cites this paper
• Prediction of Vascular Risk after Stroke — Protocol and Pilot Data of the Prospective Cohort with Incident Stroke (PROSCIS)

  2013cites this paper
• Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.

  2013cites this paper
• How to Improve the Performance of Intraoperative Risk Models: An Example with Vital Signs Using the Surgical Apgar Score

  2013cites this paper
• Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease.

  2012cites this paper
• Clinically relevant measures of fit? A note of caution.

  2012cites this paper
• Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context.

  2012cites this paper
• New metrics for assessing diagnostic potential of candidate biomarkers.

  2012cites this paper
• Development and Validation of a Coronary Risk Prediction Model for Older U.S. and European Persons in the Cardiovascular Health Study and the Rotterdam Study

  2012cites this paper
• Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis.

  2011cites this paper
• Genetic epidemiology with a Capital E, ten years after

  2011cites this paper